Search

Home > BioCentury This Week > Ep. 154 - Madrigal in NASH, Moderna & Neoantigens, the Distillery
Podcast: BioCentury This Week
Episode:

Ep. 154 - Madrigal in NASH, Moderna & Neoantigens, the Distillery
Category: Science & Medicine
Duration: 00:19:26
Publish Date: 2022-12-20 00:00:00
Description:

Phase III results for resmetirom from Madrigal Pharmaceuticals are more than enough for a regulatory submission in non-alcoholic steatohepatitis, said BioCentury Director of Biopharma Intelligence Paul Bonanos. Bonanos and colleagues discuss what Madrigal got right in running its trial for the challenging NASH indication, and what’s next in the pipeline. BioCentury’s editors also assess highly anticipated, heavily scrutinized data from Moderna among other 4Q22 readouts from neoantigen programs, as well as translational highlights from BioCentury’s Distillery.
Total Play: 0